These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046]. Ohsugi S. Nihon Geka Hokan; 1986 Mar 01; 55(2):297-305. PubMed ID: 3827476 [No Abstract] [Full Text] [Related]
24. Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). Tomoda H. Am Heart J; 1986 Oct 01; 112(4):696-704. PubMed ID: 3532743 [Abstract] [Full Text] [Related]
25. Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation. Teraoka S, Takahashi K, Toma H, Sanaka T, Yamaguchi Y, Tanabe K, Sato H, Kawaguchi H, Oba S, Nakajima I. Transplant Proc; 1987 Oct 01; 19(5):3664-8. PubMed ID: 3313883 [No Abstract] [Full Text] [Related]
26. Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris. Hendra T, Collins P, Penny W, Sheridan DJ. Int J Cardiol; 1984 Mar 01; 5(3):382-5. PubMed ID: 6538553 [Abstract] [Full Text] [Related]
27. OKY-1581, a potential selective thromboxane synthetase inhibitor. Feuerstein N, Ramwell PW. Eur J Pharmacol; 1981 Feb 19; 69(4):533-4. PubMed ID: 7195815 [No Abstract] [Full Text] [Related]
28. Effect of combined administration of low dose cyclosporine A with a thromboxane synthetase inhibitor on acute cardiac allograft rejection. Sakurai Y, Kagawa K, Kato Y, Otani H, Nonoyama A. Transplant Proc; 1990 Aug 19; 22(4):1686-8. PubMed ID: 2389433 [No Abstract] [Full Text] [Related]
29. In vivo inhibition of thromboxane synthetase in infarcted canine myocardium. McCluskey ER, Kramer JB, Corr PB, Needleman P. Biochem Biophys Res Commun; 1984 Jun 15; 121(2):552-7. PubMed ID: 6539597 [Abstract] [Full Text] [Related]
31. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. Casey LC, Fletcher JR, Zmudka MI, Ramwell PW. J Pharmacol Exp Ther; 1982 Aug 15; 222(2):441-6. PubMed ID: 6896528 [Abstract] [Full Text] [Related]
37. [Use of a thromboxane synthetase inhibitor for the protection of platelet number and function during extracorporeal circulation. Experimental study]. Massonnet Castel S, Pelissier E, Fabiani JN, Terrier E. Agressologie; 1983 Dec 15; 24(12):605-8. PubMed ID: 6686919 [No Abstract] [Full Text] [Related]